Aspirin as adjuvant therapy for colorectal cancer - Reinterpreting paradigms

Nature Reviews Clinical Oncology

Volumn 9, Issue 10, 2012, Pages 561-570

  Chia, Whay Kuang ^a   Ali, Raghib ^b   Toh, Han Chong ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; TUMOR MARKER;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COLON ADENOMA; COLORECTAL CANCER; CPG ISLAND; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; METASTASIS; MISMATCH REPAIR; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; PROGNOSIS;

EID: 84867101876     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.137     Document Type: Review

References (112)

1. Ferlay, J. et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [online], http://globocan.iarc.fr (2012).
2. Wolmark, N. et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J. Natl Cancer Inst. 80, 30-36 (1988).
3. Moertel, C. G. et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med. 122, 321-226 (1995).
4. O'Connell, M. J. et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J. Clin. Oncol. 15, 246-250 (1997).
5. Poplin, E. A. et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J. Clin. Oncol. 23, 1819-1825 (2005).
6. Chau, I. et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann. Oncol. 16, 549-557 (2005).
7. Twelves, C. et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 352, 2696-2704 (2005).
8. Andre, T. et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350, 2343-2351 (2004).
9. Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional flurouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer. PETACC-3. J. Clin. Oncol. 27, 3117-3125 (2009).
10. Ychou, M. et al. A phase III randomized trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann. Oncol. 20, 674-680 (2009).
11. Saltz, L. B. et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol. 25, 3456-3461 (2007).
12. Chau, I. & Cunningham, D. Adjuvant chemotherapy for colon cancer -what, when and how. Ann. Oncol. 9, 1347-1359 (2006).
13. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
14. Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013-2019 (2008).
15. Bergers, G. & Benjamin, L. E. Angiogenesis: Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410 (2003).
16. Diaz-Rubio, E. & Schmoll, H. J. The future development of bevacizumab in colorectal cancer. Oncology 69 (S3), 34-45 (2005).
17. Allegra, C. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 29, 11-16 (2011).
18. De Gramont, A. et al. AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer [abstract]. J. Clin. Oncol. 29 (Suppl. 4), a362 (2011).
19. Alberts, S. R. et al. Effect of oxaliplatin, flurouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307, 1383-1393 (2012).
20. Thun, M. J., Jacobs, E. J. & Patrono, C. The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol. 9, 259-267 (2012).
21. Fuchs, C. S. et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from intergroup trial CALGB 89803 [abstract]. J. Clin. Oncol. 23 (Suppl. 16), a3530 (2005).
22. Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302, 649-659 (2009).
23. Zell, J. A. et al. Non-steroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer 115, 5662-5671 (2009).
24. Coghill, A. E. et al. Pre-diagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 60, 491-498 (2011).
25. Bastiaannet, E. et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br. J. Cancer 106, 1564-1570 (2012).
26. Rothwell, P. et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379, 1591-1601 (2012).
27. Ali, R., Toh, H. C. & Chia, W. K. The utility of aspirin in Dukes C and high risk Dukes B colorectal cancer -the ASCOLT study: study protocol for a randomized controlled trial. Trials 12, 261 (2011).
28. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01150045 (2012).
29. Sandler, R. S. et al. A randomised trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348, 883-890 (2003).
30. Baron, J. A. et al. A randomised trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891-899 (2003).
31. Logan, R. F. et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134, 29-38 (2008).
32. Benamouzig, R. et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125, 328-336 (2003).
33. Bertagnolli, M. M. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355, 873-884 (2006).
34. Arber, N. et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355, 885-895 (2006).
35. Baron, J. A. et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131, 1674-1682 (2006).
36. Meyskens, F. L. et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev. Res. 1, 32-38 (2008).
37. Giardiello, F. M. et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328, 1313-1316 (1993).
38. Labayle, D. et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101, 635-639 (1991).
39. Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952 (2000).
40. Hallak, A. et al. Rofecoxib reduces polyp recurrences in familial polyposis. Dig. Dis. Sci. 48, 1998-2002 (2003).
41. Burn, J. et al. The long-term impact of aspirin on cancer risk in carriers of hereditary colorectal cancer: the CAPP2 randomized control trial. Lancet 378, 2081-2087 (2011).
42. Thun, M. J. et al. Aspirin use and risk of fatal cancer. Cancer Res. 53, 1322-1327 (1993).
43. Chan, A. T. et al. Aspirin dose and duration of use and the risk of colorectal cancer in men. Gastroenterology 134, 21-28 (2008).
44. Chan, A. T. et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294, 914-923 (2005).
45. Schreinemachers, D. M. & Everson, R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5, 138-146 (1994).
46. Giovannucci, E. et al. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333, 609-614 (1995).
47. Impreriale, T. F. Aspirin and the prevention of colorectal cancer. N. Engl. J. Med. 348, 879-880 (2003).
48. Flossmann, E. & Rothwell, P. M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369, 1603-1613 (2007).
49. Rothwell, P. M. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20 year follow-up of five randomised trials. Lancet 376, 1741-1750 (2010).
50. Rothwell, P. M. et al. Effect of aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377, 31-41 (2011).
51. Rothwell, P. M. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379, 1602-1612 (2012).
52. McNeal, C. New data on aspirin and colorectal cancer brings calls for new guidelines, more research. J. Natl Cancer Inst. 104, 172-174 (2012).
53. Creagan, E. T. et al. A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J. Clin. Oncol. 9, 2104-2109 (1991).
54. Lebeau, B. et al. No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomiszed clinical trial of 303 patients. Cancer 71, 1741-1745 (1993).
55. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813-823 (2006).
56. De Gramont, A. et al. From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin. Oncol. 38, 521-532 (2011).
57. Watanabe, K. et al. Predictive factors for pulmonary metastasis after curative resection of rectal cancer without preoperative chemoradiotherapy. Dis. Colon Rectum 54, 989-998 (2011).
58. Hamano, T. et al. Inguinal lymph node metastases are recognized with high frequency in rectal adenocarcinoma invading the dentate line. The histological features at the invasive front may predict inguinal lymph node metastasis. Colorectal Dis. 10, e200-e205 (2010).
59. Maslekar, S. et al. Mesorectal grades predict recurrences after curative resection for rectal cancer. Dis. Colon Rectum 50, 168-175 (2007).
60. Kapiteijn, E. et al. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br. J. Surg. 89, 1142-1149 (2002).
61. Yamauchi, M. et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61, 847-854 (2012).
62. Yamauchi, M. et al. Colorectal cancer: a tale of two sides or a continuum? Gut 61, 794-797 (2012).
63. Wong, J. J. L. et al. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. Mod. Pathol. 24, 396-411 (2011).
64. Lao, V. V. & Grady, W. M. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 8, 686-700 (2011).
65. Ogino, S. & Goel, A. Molecular classification and correlates in colorectal cancer. J. Mol. Diagn. 10, 13-27 (2008).
66. Curtin, K., Slattery, M. L. & Samowitz, W. S. CpG island methylation in colorectal cancer: past, present and future. Pathol. Res. Int. 2011, 902674 (2011).
67. Hughes, L. A. E. et al. The CpG island methylator phenotype in colorectal cancer: Progress and problems. Biochim. Biophys. Acta 1825, 77-85 (2012).
68. Mahipal, A. et al. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol. Biomarkers Prev. 15, 1785-1790 (2006).
69. Rosenberg, L. et al. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl Cancer Inst. 159, 161-166 (1991).
70. Berger, J. S., Brown, D. L. & Becker, R. C. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am. J. Med. 121, 43-49 (2008).
71. Ellenberg, J. H. Selection bias in observational and experimental studies. Stat. Med. 13, 557-567 (1994).
72. Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356, 2131-2142 (2007).
73. Ogino, S. et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin. Cancer Res. 14, 8221-8227 (2008).
74. Soumaoro, L. T. et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin. Cancer Res. 10, 8465-8471 (2004).
75. Midgley, R. S. et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR Trial. J. Clin. Oncol. 28, 4575-4580 (2010).
76. McQuaid, K. R. & Laine, L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 119, 624-638 (2006).
77. Raju, N. et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am. J. Med. 124, 621-629 (2011).
78. Derry, S. & Loke, Y. K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321, 1183-1187 (2000).
79. Seshasai, S. R. et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch. Intern. Med. 172, 209-216 (2012).
80. Laine, L. Review article: gastrointestinal bleeding with low-dose aspirin -what's the risk? Aliment. Pharmacol. Ther. 24, 897-908 (2006).
81. Berger, J. S., Lala, A., Krantz, M. J., Baker, G. S. & Hiatt, W. R. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials. Am. Heart J. 162, 115-124 (2011).
82. Lanas, A., Wu, P., Medin, J. & Mills, E. J. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin. Gastroenterol. Hepatol. 9, 762-768 (2011).
83. Ruffin, M. T. et al. Supression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J. Natl Cancer Inst. 89, 1152-1160 (1997).
84. Sample, D. et al. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol. Biomarkers Prev. 11, 275-279 (2002).
85. [No authors listed] Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N. Engl. J. Med. 321, 129-135 (1989).
86. Cook, N. R. et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294, 47-55 (2005).
87. Dajani, E. Z. & Islam, K. Cardiovascular and gastrointestinal toxicity of selective cyclooxygenase-2 inhibitors in man. J. Physiol. Pharmacol. 59 (Suppl. 2), 117-133 (2008).
88. Tanaka, S. & Imamura, Y. International Comparisons of Cumulative Risk of Colorectal Cancer, from Cancer Incidence in Five Continents Vol. VIII. Jpn J. Clin. Oncol. 36, 186-187 (2006).
89. Holmes, M. D. et al. COX-2 expression predicts worse breast cancer prognosis and does not modify association with aspirin. Breast Cancer Res. 130, 657-662 (2011).
90. Ogino, S., Chan, A. T., Fuchs, C. S. & Giovannucci, E. Molecular pathologic epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60, 397-411 (2011).
91. Ogino, S. & Stampfer, M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J. Natl Cancer Inst. 102, 365-366 (2010).
92. Begg, C. B. A strategy for distinguishing optimal cancer subtypes. Int. J. Cancer 129, 931-937 (2011).
93. Fridman, W. H., Pages, F., Fridman, C. S. & Galon, J. The immune contexture in human tumors: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
94. Ogino, S., Galon, J., Fuchs, C. S. & Dranoff, G. Cancer Immunology-analysis of host and tumor factors for personalized medicine. Nat. Rev. Clin. Oncol. 8, 711-719 (2011).
95. Hahn, M. A. et al. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res. 68, 10280-10289 (2008).
96. Edwards, R. A. et al. Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. Cancer Res. 69, 6423-6429 (2009).
97. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation and cancer. Cell 140, 883-899 (2010).
98. Tuynman, J. B. et al. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 68, 1213-1220 (2008).
99. Hawcroft, G. et al. Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 23, 107-114 (2002).
100. Boon, E. M. et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br. J. Cancer 12, 224-229 (2004).
101. Castellone, M. D. et al. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-b-catenin signaling axis. Science 310, 1504-1510 (2005).
102. Herfs, M., Hubert, P. & Delvenne, P. Epithelial metaplasia: adult stem cell reprogramming and (pre)neoplastic transformation mediated by inflammation? Trends Mol. Med. 15, 245-253 (2009).
103. Soria, G. et al. Inflammatory mediators in breast cancer: coordinate expression of TNFa & IL-1b with CCL2 and CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11, 130 (2011).
104. Lopez-Novoa, J. M. & Nieto, M. A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol. Med. 1, 202-314 (2009).
105. Jang, T. J., Jeon, K, H. & Jung, K. H. Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers. Yonsei Med. J. 50, 818-824 (2009).
106. Dohadwala, M. et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E2 induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 66, 5338-5345 (2006).
107. Rius, J. et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453, 807-811 (2008).
108. Liu, X. et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 29, 442-450 (2010).
109. Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 11, 123-134 (2011).
110. Kamezis, T. et al. VEGF-D promotes tumor metastasis by regulating prostaglandin produced by the collecting lymphatic endothelium. Cancer Cell 21, 181-195 (2012).
111. Boer, H. C. et al. Fibrin and activated platelets cooperatively guide stem cells to a vascular injury and promote differentiation towards an endothelial cell phenotype. Arterioscler. Thromb. Vasc. Biol. 26, 1653-1659 (2006).
112. Kim, M. Y. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315-1326 (2009).